Detail akcie Livanova online

Business Summary: LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
Financial Summary: BRIEF: For the three months ended 31 March 2025, LivaNova PLC revenues increased 7% to $316.9M. Net loss increased from $41.9M to $327.3M. Revenues reflect Cardiopulmonary segment increase of 13% to $176.3M, Neuromodulation segment increase of 4% to $138.9M, United States segment increase of 5% to $169.2M, Rest of World segment increase of 10% to $88M, Europe segment increase of 10% to $59.7M.